Anakinra in COVID-19: important considerations for clinical trials.
作者信息
King Andrew, Vail Andy, O'Leary Claire, Hannan Cathal, Brough David, Patel Hiren, Galea James, Ogungbenro Kayode, Wright Megan, Pathmanaban Omar, Hulme Sharon, Allan Stuart
机构信息
Division of Cardiovascular Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Salford Royal National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M6 8HD, UK.
Centre for Biostatistics, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
出版信息
Lancet Rheumatol. 2020 Jul;2(7):e379-e381. doi: 10.1016/S2665-9913(20)30160-0. Epub 2020 May 21.
Abstract
摘要
相似文献
1
Anakinra in COVID-19: important considerations for clinical trials.阿那白滞素用于新型冠状病毒肺炎：临床试验的重要考量因素
Lancet Rheumatol. 2020 Jul;2(7):e379-e381. doi: 10.1016/S2665-9913(20)30160-0. Epub 2020 May 21.
2
Interleukin-1 blocking agents for treating COVID-19.白细胞介素-1 阻断剂治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jan 26;1(1):CD015308. doi: 10.1002/14651858.CD015308.
3
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
4
A meta analysis on the utility of Anakinra in severe COVID-19 disease.一项关于阿那白滞素在严重 COVID-19 疾病中的效用的荟萃分析。
Cytokine. 2023 Sep;169:156311. doi: 10.1016/j.cyto.2023.156311. Epub 2023 Aug 1.
5
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.阿那白滞素治疗 COVID-19 患者：系统评价和荟萃分析。
Eur J Med Res. 2023 Feb 25;28(1):100. doi: 10.1186/s40001-023-01072-z.
6
Anakinra-An Interleukin-1 Receptor Antagonist for COVID-19.阿那白滞素-一种用于治疗 COVID-19 的白细胞介素-1 受体拮抗剂。
Am J Ther. 2023;30(2):e108-e116. doi: 10.1097/MJT.0000000000001603. Epub 2023 Feb 22.
7
Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.阿那白滞素与住院COVID-19患者较低死亡率无关：一项随机对照试验的系统评价和荟萃分析。
Rev Med Virol. 2023 Mar;33(2):e2418. doi: 10.1002/rmv.2418. Epub 2023 Jan 4.
8
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.阿那白滞素治疗 COVID-19 患者：非随机队列研究的荟萃分析。
Eur J Intern Med. 2021 Apr;86:34-40. doi: 10.1016/j.ejim.2021.01.016. Epub 2021 Feb 5.
9
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial.早期可溶性尿激酶型纤溶酶原受体血浆引导下阿那白滞素治疗新冠肺炎肺炎的疗效和安全性：SAVE-MORE随机试验的亚组分析
EClinicalMedicine. 2023 Feb;56:101785. doi: 10.1016/j.eclinm.2022.101785. Epub 2022 Dec 26.
10
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.阿那白滞素治疗危重症 COVID-19 患者：一项前瞻性队列研究。
Crit Care. 2020 Dec 10;24(1):688. doi: 10.1186/s13054-020-03364-w.
引用本文的文献
1
Examining efficacy and safety of ethyl acetate extract from as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.考察[具体植物名称]乙酸乙酯提取物作为COVID-19辅助疗法的疗效和安全性：一项随机、多中心、对照临床试验。 （注：原文中“as complementary therapy in COVID-19”前缺少具体植物名称，翻译时添加了[具体植物名称]以保证句子完整通顺）
Avicenna J Phytomed. 2024 Nov-Dec;14(6):699-710. doi: 10.22038/AJP.2024.24523.
2
The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction.纤溶酶原激活物抑制剂-1启动子中4G/5G多态性对新冠病毒疾病严重程度和内皮功能障碍的影响。
Front Immunol. 2024 Aug 30;15:1445294. doi: 10.3389/fimmu.2024.1445294. eCollection 2024.
3
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.新冠病毒治疗药物耐药性和副作用的可能机制：其根除的瓶颈。
Daru. 2024 Dec;32(2):801-823. doi: 10.1007/s40199-024-00524-z. Epub 2024 Jul 19.
4
Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting.新冠病毒感染患者不断演变的临床表现及预后：罗马尼亚一家医院环境中新冠病毒变异株浪潮的比较分析
Pathogens. 2023 Dec 14;12(12):1453. doi: 10.3390/pathogens12121453.
5
Characterization of T Helper 1 and 2 Cytokine Profiles in Newborns of Mothers with COVID-19.新型冠状病毒肺炎母亲所生新生儿中辅助性T细胞1型和2型细胞因子谱的特征分析
Biomedicines. 2023 Mar 15;11(3):910. doi: 10.3390/biomedicines11030910.
6
COVID-19 and the role of cytokines in this disease.新型冠状病毒肺炎（COVID-19）以及细胞因子在该疾病中的作用。
Inflammopharmacology. 2022 Jun;30(3):789-798. doi: 10.1007/s10787-022-00992-2. Epub 2022 May 4.
7
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.新型冠状病毒肺炎被动免疫治疗的最新进展：基于证据的方法和临床试验。
Int Immunopharmacol. 2022 Aug;109:108786. doi: 10.1016/j.intimp.2022.108786. Epub 2022 Apr 21.
8
Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis.阿那白滞素治疗对 COVID-19 患者炎症生物标志物降低的疗效：一项荟萃分析。
J Clin Lab Anal. 2022 Jun;36(6):e24434. doi: 10.1002/jcla.24434. Epub 2022 Apr 18.
9
Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome.基于干细胞的 COVID-19 相关急性呼吸窘迫综合征治疗方法。
J Cell Mol Med. 2022 May;26(9):2483-2504. doi: 10.1111/jcmm.17265. Epub 2022 Apr 14.
10
-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.第二卷：SARS-CoV-2 大流行两年后感染或 mRNA 疫苗接种、药物治疗和非药物管理后的免疫。
Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309.
本文引用的文献
1
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
2
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.在中重度新型冠状病毒肺炎中使用阿那白滞素靶向炎症级联反应：病例系列
Ann Rheum Dis. 2020 Oct;79(10):1381-1382. doi: 10.1136/annrheumdis-2020-217706. Epub 2020 May 6.
3
The trinity of COVID-19: immunity, inflammation and intervention.COVID-19 的三位一体：免疫、炎症和干预。
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
4
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.持续静脉输注阿那白滞素以平息巨噬细胞活化综合征中的细胞因子风暴
ACR Open Rheumatol. 2020 May;2(5):276-282. doi: 10.1002/acr2.11135. Epub 2020 Apr 21.
5
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子（包括白细胞介素 6）在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
6
Treatment for severe acute respiratory distress syndrome from COVID-19.新型冠状病毒肺炎所致严重急性呼吸窘迫综合征的治疗
Lancet Respir Med. 2020 May;8(5):433-434. doi: 10.1016/S2213-2600(20)30127-2. Epub 2020 Mar 20.
7
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Pharmacokinetics of Anakinra in Subjects of Heavier vs. Lighter Body Weights.阿那白滞素在体重较重与较轻受试者中的药代动力学。
Clin Transl Sci. 2019 Jul;12(4):371-378. doi: 10.1111/cts.12622. Epub 2019 Apr 8.
10
Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.阿那白滞素治疗巨噬细胞活化综合征：单中心经验和文献系统评价。
Clin Rheumatol. 2018 Dec;37(12):3329-3335. doi: 10.1007/s10067-018-4095-1. Epub 2018 Apr 16.
Zotero 插件